At the London Bullion Market Association's conference, experts highlighted gold's resilience despite rising global bond yields, suggesting growing investor worries about mounting government debt and currency debasement. Traditionally, higher bond yields pressure gold prices, but this relationship is weakening as debt levels surge and governments tolerate inflation to manage borrowing costs. This shift may lead to increased institutional gold demand as bond markets face challenges, with strong ongoing demand from Asia and younger investors viewing gold as a wealth protector. While short-term volatility is expected, the long-term outlook for gold remains positive amid persistent fiscal deficits and inflation concerns worldwide.
Gold's role amid debt concerns is highlighted with Pluang's market data providing context. For readers following market breadth, 98 of 150 priced US stocks rose while 52 fell. Notable movers include AFRM at USD 74.87 with a 1-day change of +5.79%, SHOP at USD 159.55 with +5.39%, and U at USD 45.82 with +5.07%. Data is as of Oct 06, 2026 02:21 WIB.
Levi Strauss & Co. is set to report its Q3 2026 earnings on October 7, with analysts forecasting adjusted earnings of $0.36 per share and revenue of $1.61 billion, marking a 4.5% increase year-over-year. Strong denim demand and growth in Europe, Asia...
On October 5, 2026, five notable stocks experienced double-digit declines. Sphere Entertainment fell 13.6% after a downgrade from Craig-Hallum, while C.H. Robinson dropped 10.9% following its announcement to acquire RXO for $5.8 billion. Velo3D, Boos...
Applied Digital is set to report a fiscal Q1 loss of $0.30 per share on $116.3 million revenue, reflecting ongoing investments in AI and high-performance data centers. The company has expanded its Polaris Forge 1 campus to 250 MW operational capacity...
Investment firm Needham increased its price target for Vaxcyte to $122 from $110 following positive Phase 3 trial results for Vaxcyte's VAX-31 pneumococcal vaccine. The vaccine met all primary endpoints in the OPUS-1 trial, showing noninferiority to ...
GMAB's investigational drug Rina-S demonstrated a 45.9% confirmed response rate in a Phase 1/2 trial for platinum-resistant ovarian cancer, with a median response duration of 12.1 months and median progression-free survival of 9.5 months. Despite ser...
